A Study of Intranasal Esketamine Medication in the Treatment of Major Depressive Disorder and its Symptoms in Children 12 to 17 Years Old

What we are studying

The purpose of this study is to see if esketamine is useful for treating children 12 to 17 years of age with Major Depressive Disorder (MDD) who are currently thinking about killing themselves.

Who is Eligible

  • All Genders
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • All Ethnicities
  • Ages 12 - 17

Eligibility Criteria

  • Diagnosed with Major Depressive Disorder

What is involved

  • Randomized into one of two groups that will either take the medication or receive a placebo
  • Review of medical history and medications
  • Completing a Physical Exam and Vital Signs
  • Electrocardiogram
  • Nasal examination
  • Complete Depression Rating Scale
  • Patient questionnaires
  • Urine sample and Blood Draws
  • Receive Study Drug and Psychological Therapy
  • Pulse oximetry test

Compensation

Participants will receive $75 per visit to help cover their expenses for attending study visits and $25 as compensation for their time associated with completing the protocol required remote contacts with the site personnel.

Contact Information

Study Coordinator
Barbara Lasater
Email
336-716-5348
Phone
blasater@wakehealth.edu
Principal Investigator
Matthew Hough

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.